TITLE

Increased plasma neurotensin concentrations in patients with Parkinson's disease

AUTHOR(S)
Schimpff, R.-M.; Avard, C.; Fénelon, G.; Lhiaubet, A.-M.; Tennezé, L.; Vidailhet, M.; Rostène, W.
PUB. DATE
June 2001
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jun2001, p784
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66877945

 

Related Articles

  • Levodopa availability improves with progression of Parkinson�s disease. Woitalla, Dirk; Goetze, Oliver; Kim, Jeong I.; Nikodem, Alice B.; Schmidt, Wolfgang E.; Przuntek, Horst; M�ller, Thomas // Journal of Neurology;Sep2006, Vol. 253 Issue 9, p1221 

    Previous pharmacokinetic trials with standard levodopa formulations showed a different behaviour of levodopa degradation in plasma of patients with Parkinson�s disease (PD) in various stages. To investigate associations between levodopa plasma levels in relation to the scored intensity of...

  • Acute Postoperative Confusion and Hallucinations in Parkinson Disease. Golden, William E.; Lavender, Robert C.; Metzer, W. Steven // Annals of Internal Medicine;8/1/89, Vol. 111 Issue 3, p218 

    Determines whether patients with Parkinson disease are at an increased risk for postoperative confusion. Effect of parkinson disease on patients; Mental conditions associated with idiopathic parkinsonism; Medications used for the patients; Risk associated with the parkinson disease.

  • Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease: Guidelines for Effective Use. Davis, T.L. // CNS Drugs;1998, Vol. 10 Issue 4, p239 

    Although orally administered levodopa is the mainstay treatment for Parkinson's disease, its use is often complicated by a fluctuating response. This may be improved by strategies that provide more constant dopaminergic stimulation. Catechol-O-methyltransferase (COMT) catalyses the O-methylation...

  • The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer. Sgourakis, George; Papapanagiotou, Aggeliki; Kontovounisios, Christos; Karamouzis, Michalis; Dedemadi, Georgia; Goumas, Constantine; Karaliotas, Constantine; Papavassiliou, Athanasios // Tumor Biology;Jun2014, Vol. 35 Issue 6, p5993 

    This pilot study aimed to determine the feasibility of serum neurotensin/IL-8 values being used as a screening tool for colorectal cancer. Fifty-six patients and 15 healthy controls were assigned to seven groups according to their disease entity based on theater records and histology report....

  • Peripheral Inflammatory Biomarkers and Risk of Parkinsons Disease. Honglei Chen; Eilis J. OReilly; Michael A. Schwarzschild; Alberto Ascherio // American Journal of Epidemiology;Jan2008, Vol. 167 Issue 1, p90 

    Experimental and postmortem evidence indicates a role of neuroinflammation in the pathogenesis of Parkinsons disease. The authors prospectively examined whether plasma concentrations of inflammatory biomarkers assessed before Parkinsons disease diagnosis were predictive of future risk of the...

  • Neurodegenerative Diseases.  // Current Medical Literature: Neurology;2010, Vol. 26 Issue 3, p92 

    The article summarizes medical studies on neurodegenerative diseases published as of September 2010. A study published in "Movement Disorders," compared findings of 25 patients with tremulous scans without evidence of dopaminergic deficits with those of 25 patients with tremor-dominant...

  • Hypermagnesaemia and hypophosphataemia after ingestion of magnesium sulphate. Garcia-Webb, P.; Bhagat, C.; Oh, T.; Hart, G.; Thompson, W. // British Medical Journal (Clinical Research Edition);3/10/1984, Vol. 288 Issue 6419, p759 

    Presents a case of hypermagnesaemia and hypophosphataemia after ingestion of magnesium sulphate. Rarity of hypermagnesaemia disease; Increase of blood plasma magnesium concentration in hypermagnesaemia patient; Changes in plasma calcium and phosphate concentrations of patients.

  • Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Nyholm, Dag // Clinical Pharmacokinetics;2006, Vol. 45 Issue 2, p109 

    Pharmacotherapy for Parkinson’s disease is focused on dopaminergic drugs, mainly the dopamine precursor levodopa and dopamine receptor agonists. The elimination half-life (t½) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more...

  • Bromocriptine induced impotence in Parkinson's disease. Cleeves, Lynn; Findley, Leslie J. // British Medical Journal (Clinical Research Edition);8/8/1987, Vol. 295 Issue 6594, p367 

    Examines the bromocriptine induced impotence in patients with Parkinson's diseases. Increased sexual drive in patients with Parkinson's disease; Association of hypersexual behavior with an acute brain syndrome; Common feature of Parkinson's disease.

  • News Roundup. LeBano, Lauren // Neurology Reviews;Aug2012, Vol. 20 Issue 8, p3 

    The article presents information on research results related to neurology. According to a recent report, severe influenza increases the risk of Parkinson's disease while measles reduces the risk of Parkinson's disease. Another research reports that patients with advanced forms of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics